
PT524 – Building a Unified Psychedelic Future: Ethics, Standards, and a Path to Affordable Access, with Lia Mix, LMFT, CPTR
Psychedelics Today
Understanding and Addressing Vulnerability in Psychedelic Therapy
The FDA gathers representatives of stakeholders in public health to assess new therapies like MDMA therapy. During a recent meeting on June 4th, stakeholders, new to the process and therapy, expressed deep fear of harm in psychedelic therapy due to its nature of putting individuals in a vulnerable state. The meeting lacked input from practitioners reassuring their capability in understanding, preventing, identifying, and addressing harms in psychedelic therapy.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.